肺癌治療之新穎策略的研發

CMUR > College of Medicine > Graduate Institute of Cancer Biology > Research reports > Item 310903500/12564

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/12564

Title:	肺癌治療之新穎策略的研發
Authors:	洪明奇(Mien-Chie Hung);李龍緣(Long-Yuan Li)
Contributors:	醫學院癌症生物學研究所;中國附醫院長室
Keywords:	肺癌;臨床資訊;組織庫核心實驗室;lung cancer;clinical information;tissue core laboratory
Date:	2008-12-31
Issue Date:	2009-09-01 15:57:48 (UTC+8)
Abstract:	肺癌是最常見的癌症死因，約佔癌症死亡人數的17％。雖然現今醫療技術進步快速，然而肺癌的5年存活率只有12-15％。非小細胞肺癌是肺癌的主要類型。大約有30％的患者可以在疾病早期診斷並接受手術治療。然而，40％的病人在五年內有復發的情形。此外，轉移是肺癌治療失敗的另一主要原因。因此肺癌的早期診斷和改善預後是相當重要的。藉由蛋白質體學、分子生物學的發展，將有助於找到肺癌的相關危險因子，釐清致癌機轉，以改善肺癌的治療方式甚或是達到預防肺癌的目的。因此，臨床和病理資訊的整合對於臨床治療和基礎研究而言，是不可或缺的。為此我們計畫建置肺癌組織及其臨床資訊核心，作為一個研究平台，提供完善的檢體和臨床病理資料以供研究人員進行分析、統計。我們將遵守標準作業流程，使其有效且正確地操作和儲存檢體，並建立肺癌病人的臨床病理資料（包括︰家族史、抽菸有無、預後）。我們預期所得到的結果將可應用在生物標記、危險因子和流行病學分析等方面，相信對於肺癌研究的進展將有一定程度的裨益。 Lung cancer is the most common cause of death from cancer worldwide. Among cancer mortality patients, 17% were caused by lung cancer. Although current improvement of medical science, the overall 5-year survival time in lung cancer is 9% in male and 12% in female in Taiwan area, and 15% in the United States. Non-small cell lung cancer (NSCLC) is the main cell type of lung cancer. There are only 30% NSCLC can be diagnosed in their early stage. Among them, 40% will relapse within 5 years after potentially curative treatment. Thus, current staging methods are inadequate for predicting the outcome of treatment of NSCLC. By using advance of proteomics and molecular biology, it can help us to find various relative risk factors, to clarify carcinogenesis, to improve therapeutic methods, and even to prevent NSCLC. Therefore, it is essential to collaborate the information of both clinical therapy and basic study. Our goal is to set up a lung cancer tissue core laboratory and clinical information core facility. As a research platform, it will offer high quality specimens and complete clinical data to researchers for further statistical analysis. We will obey standard operation process to manipulate and store the specimens efficiently and accurately. Additionally, we will build up clinical data of NSCLC database, including family history, smoking status, and prognosis. We anticipate that it will become a very good supporting research source in biomakers, risk factors, and epidemiology analysis of all other projects for improvement of lung cancer research.
Appears in Collections:	[Graduate Institute of Cancer Biology] Research reports

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	274	View/Open

Loading...